Novel therapeutic approaches in the treatment of solitary fibrous tumors: A call for a combination therapy
Abstract
A solitary fibrous tumor (SFT) is a rare mesenchymal tumor with a high risk of local recurrence and a metastatic potential. Because of the rarity of the disease, the data regarding possible nonsurgical treatment options are limited.
Until recently, most extensive reports regarding nonsurgical SFT treatment were based on case reports. Although SFTs present rare diseases and may have a benign biological nature, local recurrence and metastatic behavior are also highly prevalent.
Based on the limited data, we aim to highlight that similarly to soft-tissue sarcomas, radiotherapy, targeted therapy, and immunotherapy should become part of therapeutic algorithms in SFTs. Moreover, clinical testing of other immune checkpoint inhibitors is urgently needed, and only close interdisciplinary cooperation between surgical and nonsurgical institutions can introduce patients with SFTs to novel immunotherapeutic approaches, such as adoptive T-cell transfer and chimeric antigen receptor T-cell immunotherapy.